ABL at World Vaccine Congress 2016

ABL at World Vaccine Congress 2016

  • Mar 29-31, 2016
  • the Grand Hyatt in Washington, DC

Washington, D.C.—March 11, 2016 – ABL is attending World Vaccine Congress 2016  at the Grand Hyatt in Washington, DC from March 29 – 31st. ABL’s research and manufacturing service offerings span 6 of the co-located conferences: Cancer & Immunotherapy, Influenza & Respiratory, Emerging & Re-Emerging, Clinical Trials, Bioprocessing & Manufacturing, and Partnerships. We are excited to attend this year with newly added European capabilities in clinical research and GMP virus manufacturing.

ABL will be at Booth 115 to discuss your project goals and how ABL can address your needs. If you are joining from out of town and would like to take advantage of the proximity to ABL’s global headquarters, please email us to set up a site visit.

About ABL, Inc.

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including the U.S. Government, biopharmaceutical companies and academic entities. Notable contract manufacturing services include process and assay development, cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics in the U.S. and Europe. ABL also maintains U.S. and European immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally.

For more information visit www.ablinc.com or email us.